GESTATIONAL TROPHOBLASTIC TUMORS

被引：32

作者：

LURAIN, JR

机构：

[1] Section of Gynecologic Oncology, John I. Brewer Trophoblastic Disease Center, Northwestern University Medical School, Chicago, Illinois

来源：

SEMINARS IN SURGICAL ONCOLOGY | 1990年 / 6卷 / 06期

关键词：

choriocarcinoma; invasive mole; trophoblast;

D O I：

10.1002/ssu.2980060610

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Gestational trophoblastic tumor is a term applied to invasive mole, choriocarcinoma, and placental‐site trophoblastic tumor. The overall cure rate in the treatment of these gestational trophoblastic tumors now exceeds 90%. This high success rate is the result of (1) inherent sensitivity of trophoblastic tumors to chemotherapy, (2) ability to monitor therapy effectively with the use of human chorionic gonadotropin as a tumor marker, and (3) identification of prognostic factors which allows categorization of patients into high‐ and low‐risk groups for selection of treatment. Virtually all patients with nonmetastatic and low‐risk metastatic disease can be cured using single‐agent methotrexate or Actinomycin‐D chemotherapy. Intensive therapy with combination chemotherapy including etoposide, high‐dose methotrexate and Actinomycin D and, where indicated, adjuvant radiotherapy and surgery has resulted in cure rates of 80–90% in patients with high‐risk metastatic disease. The factors which are most important in determining response to treatment are: (1) clinicopathologic diagnosis of choriocarcinoma, (2) metastases to sites other than the lung or vagina, (3) number of metastases, (4) previous failed chemotherapy, and (5) WHO score ⩾8. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company

引用

页码：347 / 353

页数：7

共 70 条

[31]

Osathamondh R, Goldstein DP, Pastorfide GB, Actinomycin D as the primary agent for gestational trophoblastic disease, Cancer, 36, pp. 863-866, (1975)

[32]

Goldstein DP, Saracco P, Osathanondh R, Et al., Methotrexate with citrovorum factor rescue for gestational trophoblastic neoplasms, Obstet Gynecol, 51, pp. 93-96, (1978)

[33]

Berkowitz RS, Goldstein DP, Bernstein MR, Methotrexate with citrovorum factor rescue as primary therapy for gestational trophoblastic disease, Cancer, 50, pp. 2024-2027, (1982)

[34]

Berkowitz RS, Goldstein DP, Bernstein MR, Ten years' experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease, Gynecol Oncol, 23, pp. 111-118, (1986)

[35]

Wong LC, Choo YC, Ma HK, Methotrexate with citrovorum factor rescue in gestational trophoblastic disease, Am J Obstet Gynecol, 152, pp. 59-62, (1985)

[36]

Smith EB, Weed JC, Tyrey L, Et al., Treatment of nonmetastatic gestational trophoblastic disease: Results of methotrexate alone versus methotrexate‐folinic acid, Am J Obstet Gynecol, 144, pp. 88-92, (1982)

[37]

Mutch DG, Soper JT, Baker ME, Bandy LC, Et al., Role of computed axial tomography of the chest in staging patients with nonmetastatic gestational trophoblastic disease, Obstet Gynecol, 68, pp. 348-352, (1986)

[38]

Rotmensch J, Rosenshein N, Donehower R, Et al., Plasma methotrexate levels in patients with gestational trophoblastic neoplasia treated by two methotrexate regimens, Am J Obstet Gynecol, 148, pp. 730-734, (1984)

[39]

Schlaerth JB, Morrow CP, Nalick RH, Gaddis O, Single‐dose actinomycin D in the treatment of postmolar trophoblastic disease, Gynecol Oncol, 19, pp. 53-56, (1984)

[40]

Twiggs LB, Pulse actinomycin D scheduling in nonmetastatic gestational trophoblastic neoplasia: Cost‐effective chemotherapy, Gynecol Oncol, 16, pp. 190-195, (1983)

← 1 2 3 4 5 6 7 →